T cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies, including …
Yescarta First CAR T-Cell Therapy FDA Approved for Large B-Cell …
On April 1, 2022, the FDA accelerated the approval of a new indication for the CAR T-cell therapy axicabtagene ciloleucel (Yescarta; Kite Pharma) for adults with large B-cell lymphoma that is …
The journey of CAR-T therapy in hematological malignancies
Abstract Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment paradigms for hematological malignancies, with multi-line therapy-refractory patients achieving …
How Does YESCARTA® (axicabtagene ciloleucel) Work and Who …
Learn about who YESCARTA® (axicabtagene ciloleucel) is for, how it works, and important treatment considerations. See Important Safety Information & Warnings.
Large B-Cell Lymphoma | YESCARTA® (axicabtagene ciloleucel)
YESCARTA ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with large B-cell lymphoma that is refractory to first-line …
Axicabtagene Ciloleucel as Second-Line Therapy for Large B …
Dec 11, 2021 · The autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) is approved for the treatment of patients with relapsed or …
Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic …
YESCARTA | FDA
Oct 28, 2025 · For the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line …
YESCARTA® (axicabtagene ciloleucel) Patient & Caregiver Site
Learn about YESCARTA® (axicabtagene ciloleucel) a CAR T-cell therapy for certain types of non-Hodgkin lymphoma in adults. See Important Safety Information & Warnings.
Frequently Asked Questions About YESCARTA® (axicabtagene …
Mar 23, 2021 · YESCARTA is a genetically-modified autologous T-cell immunotherapy. Chimeric Antigen Receptor (CAR) T-cell therapy is a new type of treatment that utilizes a patient’s own …